机器学习模型在减少不必要靶向前列腺穿刺活检中的性能比较
本研究回顾性分析两个学术中心1884例接受前列腺磁共振成像和活检的患者数据,评估12种机器学习模型在预测临床显著前列腺癌(Gleason分级组≥2)中的表现。最佳模型可在假阴性率1.91%下减少13.07%的活检,性能在各中心间一致,但研究受限于中心数量少和缺乏特定临床数据。
要点
- 最佳机器学习模型在假阴性率1.91%下减少13.07%的活检。
- 模型性能在两个学术中心间保持一致。
- 研究受限于中心数量少和缺乏特定临床数据。
核心结论
- 机器学习增强的临床模型为预测临床显著前列腺癌提供有效且可推广的方法。
- 这些模型支持个性化风险评估和随访,辅助临床决策并提高工作流程效率。
研究设计与样本
- 回顾性分析两个学术中心1884例接受前列腺磁共振成像和活检的患者数据,时间范围为2016年至2020年或2004年至2011年。
- 评估12种机器学习模型,使用患者年龄、前列腺特异性抗原水平及密度、前列腺影像报告和数据系统/李克特评分、病灶体积和腺体体积等临床特征组合预测临床显著前列腺癌(Gleason分级组≥2)。
- 模型采用十折分割在中心内、中心间和联合中心数据集上进行训练和验证,通过受试者工作特征曲线下面积和决策曲线分析评估效果。
主要发现
- 最佳机器学习模型在假阴性率1.91%下减少13.07%的活检数量。
- 模型性能在各中心间保持一致。
临床怎么用
- 机器学习增强的临床模型可用于预测临床显著前列腺癌,支持个性化风险评估和随访,辅助临床决策并提高工作流程效率。
局限性
- 研究受限于中心数量少。
- 研究受限于缺乏特定临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Conventional core needle biopsy for prostate cancer diagnosis can lead to diagnostic uncertainty and complications, prompting exploration of alternative risk assessment approaches that use clinical and imaging features. Our aim was to evaluate the effectiveness of machine learning (ML) models in reducing unnecessary biopsies. METHODS: We conducted a retrospective analysis of data for 1884 patients across two academic centers who underwent prostate magnetic resonance imaging and biopsy between 2016 and 2020 or 2004 and 2011. Twelve ML models were assessed for prediction of clinically significant prostate cancer (csPCa; Gleason grade group ≥2) using combinations of clinical features, including patient age, prostate-specific antigen level and density, Prostate Imaging-Reporting and Data System/Likert score, lesion volume, and gland volume. The models were trained and validated using a tenfold split for intrasite, intersite, and combined-site data sets. Model effectiveness was evaluated using the area under the receiver operating characteristic curve and decision curve analysis. KEY FINDINGS AND LIMITATIONS: The best-performing ML model would reduce the number of biopsies by 13.07% at a false-negative rate of 1.91%. Performance was consistent across sites, although the study is limited by the small number of centers and the absence of specific clinical data. CONCLUSIONS AND CLINICAL IMPLICATIONS: ML-enhanced clinical models provide an effective and generalizable approach for prediction of csPCa using standard clinical data. These models allow personalized risk assessment and follow-up, support clinical decision-making, and improve workflow efficiency. PATIENT SUMMARY: Models that are enhanced by machine learning can predict the severity of prostate cancer and help doctors in tailoring treatments for individual patients. This approach can simplify health care decisions and improve clinical efficiency.
引用
- Chen F, Esmaili R, Khajir G, et al. Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies. Eur Urol Oncol. 2025. PMID: 39924390. doi:10.1016/j.euo.2025.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。